Iterum Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on March 28, 2024
21 Março 2024 - 5:30PM
Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a
clinical-stage pharmaceutical company focused on developing next
generation oral and IV antibiotics to treat infections caused by
multi-drug resistant pathogens in both community and hospital
settings, today announced that the Company will release its
fourth quarter and full year 2023 financial results before the open
of the U.S. financial markets on Thursday, March 28,
2024. Management will host a conference call at 8:30 a.m.
ET that day to discuss the Company’s financial results and
provide an update on its business.
To access the call please dial 833-470-1428 (domestic) or
404-975-4839 (international) and refer to Access Code 891047. To
pre-register for this call, please go to the following
link: https://events.q4inc.com/attendee/670450611. The audio
webcast can be accessed under “Financials & Filings” in the
Investors section of the Company’s website at www.iterumtx.com
following the call.
About Iterum Therapeutics
plc
Iterum Therapeutics plc is a clinical-stage pharmaceutical
company dedicated to developing differentiated anti-infectives
aimed at combatting the global crisis of multi-drug resistant
pathogens to significantly improve the lives of people affected by
serious and life-threatening diseases around the world. Iterum is
currently advancing its first compound, sulopenem, a novel penem
anti-infective compound, in Phase 3 clinical development with an
oral formulation. Sulopenem also has an IV formulation. Sulopenem
has demonstrated potent in vitro activity against a wide variety of
gram-negative, gram-positive and anaerobic bacteria resistant to
other antibiotics. Iterum has received Qualified Infectious Disease
Product (QIDP) and Fast Track designations for its oral and IV
formulations of sulopenem in seven indications. For more
information, please visit http://www.iterumtx.com.
Investor Contact:Judy
MatthewsChief Financial Officer 312-778-6073IR@iterumtx.com
Iterum Therapeutics (NASDAQ:ITRM)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Iterum Therapeutics (NASDAQ:ITRM)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024